4.6 Article

Excerpts from the United States Renal Data System, 2008 Annual Data Report: Atlas of Chronic Kidney Disease & End-Stage Renal Disease in the United States, National Institutes of Health NIDDK/DKUHD

期刊

AMERICAN JOURNAL OF KIDNEY DISEASES
卷 53, 期 1, 页码 S1-S374

出版社

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.ajkd.2008.10.005

关键词

-

资金

  1. National Institutes of Health [HHSN 267 2007 15002C/NO1-DK-7-5002]
  2. Minneapolis Medical Research Foundation

向作者/读者索取更多资源

This 20th Annual Data Report reports data through 2006. This year we present a new volume on chronic kidney disease (CKD) in the United States, estimating the population using National Health and Nutrition Examination Surveys. We also use diagnostic codes and laboratory data to estimate the population within employer group health plans, assess use of the new International Classification of Diseases, Ninth Revision, Clinical Modification CKD diagnosis codes, and report on morbidity, mortality, care during the transition to end-stage renal disease, and expenditures in patients with CKD. In 2006, a total of 110,854 patients started end-stage renal disease therapy, with the prevalent population reaching 506,256; a total of 18,052 transplantations were performed; and 151,502 patients had functioning grafts at year end. Program expenditures reached $33.5 billion, with $22.7 billion from Medicare accounting for 6.4% of total Medicare expenditures. The incident rate increased 3.4% to 360 per million-the highest in 5 years. Treatment targets are now reached by 93% of hemodialysis patients. Fistula use is 45.4% in prevalent patients, with attempted placements doubling since 1996. Catheter use continues to be a concern. Hemoglobin levels greater than 12 g/dL are common, particularly in some providers. First year mortality rates for incident hemodialysis patients have decreased for the first time in 11 years; however, pediatric patient survival has not improved. The rate of infectious hospitalizations in the first year of dialysis therapy now equals that of cardiovascular hospitalizations. The public health impact of kidney disease is larger than previously appreciated, and early detection, education, intervention, and risk-factor control are needed to address the heavy burden of cardiovascular disease and adverse events in this vulnerable population.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据